Regadenoson (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Regadenoson" in English language version.

refsWebsite

Global rank English rank

4^th place

2^nd place

low place

68^th place

117^th place

1^st place

447^th place

338^th place

astellas.us

Cerqueira MD (July 2004). "The future of pharmacologic stress: selective A2A adenosine receptor agonists". The American Journal of Cardiology. 94 (2A): 33D – 40D, discussion 40D-42D. doi:10.1016/j.amjcard.2004.04.017. PMID 15261132.
Kim DG, Bynoe MS (May 2016). "A2A adenosine receptor modulates drug efflux transporter P-glycoprotein at the blood–brain barrier". The Journal of Clinical Investigation. 126 (5): 1717–33. doi:10.1172/JCI76207. PMC 4855938. PMID 27043281.

"Rapiscan EPAR". European Medicines Agency. 28 September 2010. Retrieved 3 May 2020.

"Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.

Cerqueira MD (July 2004). "The future of pharmacologic stress: selective A2A adenosine receptor agonists". The American Journal of Cardiology. 94 (2A): 33D – 40D, discussion 40D-42D. doi:10.1016/j.amjcard.2004.04.017. PMID 15261132.
Kim DG, Bynoe MS (May 2016). "A2A adenosine receptor modulates drug efflux transporter P-glycoprotein at the blood–brain barrier". The Journal of Clinical Investigation. 126 (5): 1717–33. doi:10.1172/JCI76207. PMC 4855938. PMID 27043281.

"Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.